Revenue: As of FY2026 Q1, the actual value is USD 1.048 B, missing the estimate of USD 1.073 B.EPS: As of FY2026 Q1, the actual value is USD 0.79, missing the estimate of USD 0.9.EBIT: As of FY2026 Q1, the actual value is USD 244.9 M.<h3>Overall Financial Performance</h3>Hologic, Inc. reported total revenue of $1,047.8 million for the fiscal first quarter ended December 27, 2025, marking a 2.5% increase, or 1.3% on a constant currency basis, compared to the prior year period. Total Organic Revenue, excluding COVID-19 and related revenue, divested businesses, and the acquired Gynesonics business, increased by 2.9%, or 1.6% in constant currency. U.S. Revenue grew by 2.0% to $773.5 million. International Revenue increased by 4.0% to $274.3 million, but decreased by -1.0% on a constant currency basis. <h3>Profitability</h3>GAAP Gross Margin was 56.0%, a decrease of -80 basis points, primarily due to $15.3 million in increased tariff expenses. Non-GAAP Gross Margin stood at 60.1%, a decrease of -150 basis points. GAAP Operating Expenses were $349.4 million, a -0.4% decrease from $350.7 million in the prior year. Non-GAAP Operating Expenses decreased by -0.7% to $326.6 million from $329.0 million in the prior year. GAAP Operating Margin increased by 10 basis points to 22.6%. Non-GAAP Operating Margin was 29.0%, a decrease of -40 basis points, mainly due to higher tariff expenses partially offset by lower operating expenses. GAAP Net Income was $179.1 million, representing a -10.9% decrease from $201.0 million in the prior year. Non-GAAP Net Income decreased by -1.3% to $235.5 million from $238.6 million in the prior year. Adjusted EBITDA increased by 1.3% to $330.4 million from $326.0 million in the prior year. GAAP Net Margin was 17.1%, a decrease of -260 basis points. Non-GAAP Net Margin was 22.5%, a decrease of -90 basis points. <h3>Segment Revenue</h3><ul><li>Diagnostics Revenue: This segment reported $464.4 million, a decrease of -1.3%, or -2.7% in constant currency. <ul><li>Cytology and Perinatal revenue was $126.8 million, an increase of 1.1% (reported) and a decrease of -1.1% (constant currency). </li><li>Molecular Diagnostics revenue was $329.2 million, a decrease of -3.5% (reported) and -4.6% (constant currency). </li><li>Blood Screening revenue was $8.4 million, an increase of 104.9% (reported and constant currency). </li><li>Organic Diagnostics (excluding COVID-19) revenue was $428.0 million, an increase of 1.2% (reported) and a decrease of -0.3% (constant currency). </li><li>Organic Molecular (excluding COVID-19) revenue was $301.2 million, an increase of 1.2% (reported) and 0.0% (constant currency). </li></ul></li><li>Breast Health Revenue: This segment generated $375.9 million, an increase of 1.8%, or 0.8% in constant currency. <ul><li>Breast Imaging revenue was $280.0 million, a decrease of -0.6% (reported) and -1.6% (constant currency). </li><li>Interventional Breast Solutions revenue was $95.9 million, an increase of 9.6% (reported) and 8.4% (constant currency). </li><li>Organic Breast Health revenue was $375.8 million, an increase of 1.9% (reported) and 0.8% (constant currency). </li></ul></li><li>GYN Surgical Revenue: This segment’s revenue was $180.8 million, an increase of 8.7%, or 7.5% in constant currency. <ul><li>Organic Surgical (excluding Gynesonics) revenue was $171.7 million, an increase of 3.2% (reported) and 2.0% (constant currency). </li></ul></li><li>Skeletal Health Revenue: This segment reported $26.7 million, an increase of 69.0%, or 65.9% in constant currency. </li></ul><h3>Cash Flow and Balance Sheet</h3>Cash Flow from Operations was $229.9 million in the first quarter, an increase of 21.4% from $189.3 million in the prior year. Cash and Cash Equivalents stood at $2.17 billion at quarter-end, up from $1,959.5 million at September 27, 2025. Short-term Investments amounted to $197 million. Total Principal Debt as of December 27, 2025, was $2,519.0 million. <h3>Other Metrics</h3>The Adjusted Net Leverage Ratio (net debt over adjusted EBITDA) was 0.3 times. Adjusted Return on Invested Capital (ROIC) was 13.9%, a decrease of -20 basis points compared to the prior year period. COVID-19 Revenue totaled $28.0 million, consisting of $4.4 million in assay revenue and $23.6 million in other related revenue, representing a decrease of -35.8%, or -36.3% in constant currency. <h3>Outlook / Guidance</h3>Hologic, Inc. is not providing annual or quarterly financial guidance for fiscal 2026 due to its agreement to be acquired by Blackstone and TPG. Consequently, the company will not host a conference call to discuss its first quarter 2026 financial results.

Hologic | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 1.048 B